About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
MoonLake Immunotherapeutics (MLTX): Insider Trades and Fund Holdings
In the past 12 months, MoonLake Immunotherapeutics insiders reported no open-market purchases and 14 sales worth $9.34M; 14 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Aug 10, 2026NewsCompany reported: Quarterly or annual results
- Jul 27, 2026Insider saleChief Scientific Officer Kristian Reich sold $22,000 under a 10b5-1 plan
- Jul 22, 2026Insider saleChief Scientific Officer Kristian Reich sold $48,960 under a 10b5-1 plan
- Jul 21, 2026Insider saleChief Scientific Officer Kristian Reich sold $1 million under a 10b5-1 plan
- Jul 20, 2026Insider saleChief Scientific Officer Kristian Reich sold $877,933 under a 10b5-1 plan
- Jul 15, 2026Insider saleChief Scientific Officer Kristian Reich sold $322,261 under a 10b5-1 plan
- Jul 10, 2026Insider saleCEO Santos Da Silva Jorge sold $1.4 million under a 10b5-1 plan
- Jul 9, 2026Insider saleCEO Santos Da Silva Jorge sold $679,059 under a 10b5-1 plan
- Jul 1, 2026Insider saleCEO Santos Da Silva Jorge sold $956,933 under a 10b5-1 plan
- Jun 30, 2026FundRenaissance Technologies added 132% in Q2 2026 (13F filed Aug 13, 2026)
- Jun 22, 2026Insider saleCFO Matthias Bodenstedt sold $862,205 under a 10b5-1 plan
- Jun 18, 2026Insider saleCFO Matthias Bodenstedt sold $54,762 under a 10b5-1 plan
- Jun 17, 2026Insider saleCFO Matthias Bodenstedt sold $296,814 under a 10b5-1 plan
- Jun 17, 2026Insider saleChief Scientific Officer Kristian Reich sold $971,500 under a 10b5-1 plan
- Jun 16, 2026Insider saleChief Scientific Officer Kristian Reich sold $935,000 under a 10b5-1 plan
- Jun 15, 2026Insider saleChief Scientific Officer Kristian Reich sold $944,500 under a 10b5-1 plan
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Jul 29, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Jul 29 | Kristian ReichChief Scientific Officer | ▼ SELL10b5-1 | $22K |
| Jul 23 | Kristian ReichChief Scientific Officer | ▼ SELL10b5-1 | $1.00M |
| Jul 23 | Kristian ReichChief Scientific Officer | ▼ SELL10b5-1 | $49K |
| Jul 21 | Kristian ReichChief Scientific Officer | ▼ SELL10b5-1 | $878K |
| Jul 20 | Kristian ReichChief Scientific Officer | ▼ SELL10b5-1 | $322K |
| Jul 13 | Santos Da Silva JorgeCEO | ▼ SELL10b5-1 | $1.37M |
| Jul 13 | Santos Da Silva JorgeCEO | ▼ SELL10b5-1 | $679K |
| Jul 2 | Santos Da Silva JorgeCEO | ▼ SELL10b5-1 | $957K |
| Jun 23 | Matthias BodenstedtCFO | ▼ SELL10b5-1 | $862K |
| Jun 18 | Matthias BodenstedtCFO | ▼ SELL10b5-1 | $297K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Kristian Reich | Chief Scientific Officer | 0 | $0 | 8 | $5.12M |
| Santos Da Silva Jorge | CEO | 0 | $0 | 3 | $3.00M |
| Matthias Bodenstedt | CFO | 0 | $0 | 3 | $1.21M |
Buybacks and executive pay
MoonLake Immunotherapeutics spent $50 buying back its own shares in 2024.
| Year | CEO pay reported | CEO pay "actually paid" | Value of $100 invested |
|---|---|---|---|
| 2025 | $4.94M | $341K | n/a |
| 2024 | $1.41M | −$225K | n/a |
| 2023 | $1.20M | $17.0M | n/a |
From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.
A 1 of 14 insider trades reported after the deadline. How it is graded
Tracked funds that report MLTX
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 643,268 | $12.5M | ▲ +132.4% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →